Hi! You can access this lecturealong with the full library of 100+hrs educational contentacross 5 formats, plus the possibility to claim up to 30.25 CE credits bysubscribing to IOSS(€59/mo).
Login using your email address *
Lost your password?
Email address *
This course includes 19 hrs of video lectures and 11 hrs of reading material. You can access this course on-demand and claim up to 30.25 APA/ACCME credits for €400.
Hi! You can access this lecture on-demand for €120. This will give you access to this specific video for one year. No CE credits are available for on demand purchases.
Hi! You can access this lecture on-demand for €70. This will give you access to this specific video for one year. No CE credits are available for on demand purchases.
Content: PDE5 inhibitors have been used widely for more than 25 years, both with and without prescription. We often see patients that have been using them for a long time, others that have been disappointed by their efficacy and others that have tried many different types. Clinicians often try to select the most appropriate PDE5inhibitor for their patients, but this not always straightforward. Dimitrios Hatzichristou is a Professor of Urology that has been studying the efficacy of PDE5 inhibitors for more than 25 years. Triggered by two recent publications, he talks about ways of combining PDE5is according to his research data. Can one use different types of PDE5i simultaneously and expect a better outcome compared to using one type? Is there a benefit of combining PDE5i with shockwave therapy? What can one expect from such combinations? Dimitris Hatzichristou, shares the most important finding of a systematic review of all the metanalysis that they recently published on JAMA, and also goes much beyond these recent publications to share his large clinical experience on the use of PDE5inhibitors. He explains why this topic is important, what the most important findings are, how he selects the appropriate PDE5i for each patient and his view of the best clinical approach.
*Mykoniatis I, Pyrgidis N, Sokolakis I, Ouranidis A, Sountoulides P, Haidich AB, van Renterghem K, Hatzichristodoulou G, Hatzichristou D. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 Feb 1;4(2):e2036337
*Mykoniatis I, Pyrgidis N, Zilotis F, Kapoteli P, Fournaraki A, Kalyvianakis D, Hatzichristou D. The Effect of Combination Treatment With Low-Intensity Shockwave Therapy and Tadalafil on Mild and Mild-To-Moderate Erectile Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. J Sex Med. 2022 Jan;19(1):106-115.
Produced in 2022
Dimitris Hatzichristou, MD, Ph.D., FECSM, is a Professor of Urology at Aristotle University of Thessaloniki, Greece. He is also President of the Institute for the Study of Urological Diseases (ISUD), a nonprofit organization dedicated to education and awareness of Urological conditions.
He received his MD and Ph.D. degrees and completed his training in Urology at Aristotle University in Thessaloniki, Greece. Then, he completed a 2-year fellowship in Andrology at Boston University, Boston, USA, and then he worked as visiting scholar (prostate diseases) for a year at Stanford University, California, USA. Prof. Hatzichristou organized and chaired the foundation meeting of the European Society for Sexual Medicine in 1995 and served as Secretary General (1995-97), President-Elect (1999-2001), and President (2001-2004) of ESSM. He has also been a faculty member of the European School of Urology (ESU), a founding member of the European Society of Andrological Urology (ESAU), a member of the Executive Committee of the International Society for Sexual Medicine (ISSM), the EAU Committee for the guidelines on erectile dysfunction (2004-2014) and co-chairman of the Committee on “Diagnostics and Scales in Sexual Medicine” of the International Consultation in Sexual Medicine since 2004. Prof Hatzichristou has served as Review and Educational Editor for the Journal of Sexual Medicine and the Journal for Impotence Research, as an Editorial board member for Urologia Internationalis and the Journal for Sexual and Reproductive Medicine, and reviewer in major scientific journals, including European Urology, Journal of Urology, International British Journal of Urology. He has been invited speaker at more than 250 international meetings and teaching courses worldwide. He has authored 25 book chapters in international books and more than 120 review and peer-review papers with more than 15000 citations (h-factor=51).